Results 241 to 250 of about 51,615 (305)

Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes. [PDF]

J Clin Oncol
Zampini M, Riva E, Lanino L, Sauta E, Antunes Dos Reis R, Ejarque RMA, Maggioni G, Termanini A, Merlotti A, Campagna A, Dall'Olio L, Kulasekararaj A, Calvi M, Di Vito C, Bonometti A, Rahal D, Croci G, Boveri E, Gianelli U, Ponzoni M, Caselli R, Albertazzi S, Todisco G, Ubezio M, Crisafulli L, Frigo A, Lugli E, Mosca E, Acha P, Ghisletti S, Nicassio F, Santoro A, Diez-Campelo M, Solé F, Ades L, Platzbecker U, Santini V, Fenaux P, Haferlach T, Sallman D, Garcia-Manero G, Mavilio D, Remondini D, Castellani G, D'Amico S, Zeidan AM, Komrokji R, Kordasti S, Ficara F, Della Porta MG, CALR Consortium.   +50 more
europepmc   +1 more source

Cytomegalovirus IL‐10 in Plasma as a Marker of Active Infection in Allogeneic Hematopoietic Transplant Recipients: An Exploratory Study

Journal of Medical Virology, Volume 98, Issue 1, January 2026.
ABSTRACT We investigated whether plasma cytomegalovirus (CMV) IL‐10 (cmvIL‐10) levels could serve as a biomarker of active CMV replication in allogeneic hematopoietic transplant recipients (allo‐HCT) in the presence or absence of letermovir (LMV) prophylaxis. A total of 189 leftover plasma samples that tested positive for CMV DNA (Alinity m CMV assay),
Ángela Sánchez‐Simarro, Eliseo Albert, Estela Giménez, Ester Colomer, Ariadna Pérez, José Luis Piñana, Carlos Solano, David Navarro   +7 more
wiley   +1 more source

Genome sequencing in the management of myelodysplastic syndromes and related disorders. [PDF]

Haematologica
Cazzola M, Malcovati L.
europepmc   +1 more source

Identifying Potential Gaps in Care for Patients with Higher-Risk Myelodysplastic Syndromes in a Large US Health System. [PDF]

Pharmacoecon Open
Moore KJ, Engel-Nitz NM, McMahon P, Beal J, Jhaveri TZ, Williamson M, Andrade K, Steiger C, Hogea C.   +8 more
europepmc   +1 more source

US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia. [PDF]

J Clin Oncol
Kim N, Pulte ED, Ehrlich LA, Ionan AC, Haupert S, Vallejo J, Green F, Zheng N, Wang Y, Liu J, Blanco JG, Dorff SE, Booth B, Choe M, Gehrke B, Bhatnagar V, Theoret M, Pazdur R, De Claro RA, Norsworthy KJ.   +19 more
europepmc   +1 more source

Splicing of erythroid transcription factor is associated with therapeutic response in myelodysplastic syndromes. [PDF]

J Clin Invest
Aluri S, Ling T, Fraint E, Chakraborty S, Zhang K, Ahsan A, Kravets L, Poigaialwar G, Zhao R, Pradhan K, Cotton A, Bachiashvili K, Yang JI, Budhathoki A, Agarwal B, Gordon Mitchell S, Carbajal M, Sahu S, Boultwood J, Pellagatti A, Steidl U, Wickrema A, Nandakumar S, Shastri A, Suragani RN, Bowman TV, Crispino JD, Vodala S, Verma A.   +28 more
europepmc   +1 more source

Exposure-response analyses of venetoclax combined with hypomethylating agents in myelodysplastic syndromes: a retrospective study. [PDF]

Front Pharmacol
Tian JX, Zhang P, Wang XX, Li JW, Liu DX, Liu YY, Xiao ZJ, Miao WJ.   +7 more
europepmc   +1 more source

Correction to "Significance of Mutation Spots and Concurrent Gene Mutations on Prognosis and Clinical Outcomes in Myelodysplastic Syndromes with SF3B1 Mutation". [PDF]

Cancer Med
europepmc   +1 more source